• FirefoxInstall the new Firefox »
  •  Dow Down 0.58% Nasdaq Down 0.26%

    Alnylam Pharmaceuticals, Inc. (ALNY)

    -NasdaqGS
    107.23 Up 0.32(0.30%) 4:00PM EST
    Add to Portfolio
    Prev Close:106.91
    Open:106.13
    Bid:106.00 x 100
    Ask:108.50 x 100
    1y Target Est:134.11
    Beta:1.8
    Earnings Date:May 6 - May 11 (Est.)
    Day's Range:104.51 - 109.32
    52wk Range:47.03 - 111.49
    Volume:632,020
    Avg Vol (3m):717,455
    Market Cap:8.98B
    P/E (ttm):N/A
    EPS (ttm):-4.85
    Div & Yield:N/A (N/A)
    Quotes delayed, except where indicated otherwise. Currency in USD.

    Comparison

    Symbol% ChgMkt Cap
    ALNYUp 0.30%8.98B
    MRKDown 0.79%164.27B
    PFEUp 0.23%212.30B
    VRXUp 0.27%68.30B

    Key Statistics

    Forward P/E (1 yr):N/A
    P/S (ttm):177.11
    Ex-Dividend Date:N/A

    Analysts

    Annual EPS Est (Dec-15) :-3.04
    Quarterly EPS Est (Mar-15) :-0.68
    Mean Recommendation*:2.0
    PEG Ratio (5 yr expected):-0.76

    * (Strong Buy) 1.0 - 5.0 (Sell)

    Analyst Opinion | Estimates

    Business Summary

    Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs include Patisiran and Revusiran, which are in Phase ... View More
    Your browser doesn't support canvas
    SETTINGS
    Scrolling
    Speed
    Display
    Price
    Submit Feedback